LeMaitre Vascular (LMAT) has drawn investor attention after recent share price moves, with the stock closing at $101.32 on 29 July 2026. The company operates in the medical devices segment focused on vascular surgery.

Recent trading reflects that momentum in LeMaitre Vascular has cooled slightly in the very short term, with a 1 day share price return that declined 0.85%, following a strong year to date share price return of 26.38% and a 5 year total shareholder return of 83.58%.

If you are comparing LeMaitre Vascular with other healthcare focused ideas, it can be useful to widen the lens and review 41 healthcare AI stocks

After a strong run and a recent pause in momentum, the question for LeMaitre Vascular at about $101 is whether the balance of risk and potential reward still leans toward buyers as the valuation numbers are unpacked next.

Most Popular Narrative: 15% Undervalued

On the most followed narrative, LeMaitre Vascular’s fair value sits at $118.75 compared with the last close at $101.32. This sets up a clear valuation gap investors will want to understand before focusing on the assumptions behind it.

Strong pipeline of innovative biologics and next-generation products, combined with ongoing regulatory wins, enhances pricing power and product mix; this supports premium pricing and improved gross margins, with successful launches expected to materially contribute to long-term earnings growth.

Want to see what is baked into that $118.75 figure? Revenue, margins and the future P/E are all pulling weight in this story. The surprise comes from how far those earnings are projected to stretch and what multiple the market is assumed to pay for them.

Result: Fair Value of $118.75 (UNDERVALUED)

However, investors in LeMaitre Vascular still need to watch for slower organic unit growth and any pressure on pricing power that could challenge the current fair value story.

Another View on LeMaitre Vascular’s Valuation

That 15% undervalued fair value of $118.75 rests on analyst forecasts and a required return. Our ratio work tells a different story. LeMaitre Vascular trades on a P/E of 37.1x versus a fair ratio of 21.4x, the US Medical Equipment industry at 28.8x and peers at 65.8x. For you, that means the stock screens expensive against the market and industry but cheaper than its closest peers. This raises a simple question: Is this a quality premium you are comfortable paying or a valuation risk you would rather avoid?

Next Steps

With a mix of optimism and concern around LeMaitre Vascular’s valuation, it makes sense to review the full picture now and decide where you stand. For a clear summary of both the potential upside and the main watchpoints, check out the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond LeMaitre Vascular?

If LeMaitre Vascular has sharpened your focus on quality opportunities, do not stop here. Broaden your watchlist with targeted stock ideas built from proven financial filters.

• Hunt for potential value candidates by reviewing companies flagged as 55 high quality undervalued stocks.
• Target stability and capital strength by scanning stocks in the solid balance sheet and fundamentals stocks screener (45 results).
• Seek lesser known opportunities with quality metrics on your side by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.